Valuation
- Market cap
- 582,430,000
- Revenue TTM
- $0
- Net income TTM
- $-51,040,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 1,712,500
- Avg volume
- 1,302,820
- Day's range
- $8.88 – $9.38
- Shares out
- 62,159,000
- Stochastic %K
- 17%
- Beta
- 3.46
- Analysts
- Strong Sell
- Price target
- $26.41
Company profile
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated stea...
Show more
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 650 561 8600
- Website
- https://www.sagimet.com
- Address
- 155 Bovet Road, Suite 303, San Mateo, United States
Latest news
No headlines yet.
